Antifungal treatments for yeast infections
Pro Research Analysisby 
Searched over 200M research papers
Conventional Antifungal Treatments for Yeast Infections
The main classes of antifungal drugs used to treat yeast infections include azoles, polyenes, echinocandins, allylamines, and nucleoside analogues. Azoles (like fluconazole) are commonly prescribed due to their effectiveness and low toxicity, but resistance is increasingly reported, especially among non-albicans Candida species and Malassezia yeasts. Polyenes (such as amphotericin B) and echinocandins are also used, particularly for more severe or resistant infections. However, some yeasts, like Candida krusei, have intrinsic resistance to fluconazole and can quickly develop resistance to other drugs, making treatment more challenging 167.
Drug Resistance and Treatment Challenges in Yeast Infections
Drug resistance is a growing problem in the treatment of yeast infections. Mechanisms of resistance include changes in drug targets, reduced drug uptake, and the development of alternative metabolic pathways. This resistance is especially concerning in immunocompromised patients and with emerging pathogens like Candida auris, which often require alternative or combination therapies due to high resistance rates and toxicity concerns with some drugs 46710.
New and Investigational Antifungal Agents
Due to rising resistance and limited treatment options, new antifungal agents are being developed. Promising investigational drugs include fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole, VT-1598, PC945, and olorofim. These agents offer new mechanisms of action or improved safety profiles and are currently in various stages of clinical trials .
Alternative and Natural Antifungal Therapies
Researchers are exploring natural substances, such as plant extracts, essential oils, propolis, and carnosic acid, as alternative treatments for yeast infections. These natural agents have shown moderate antifungal activity, and their effectiveness can be enhanced when combined with conventional drugs like amphotericin B. However, challenges such as poor bioavailability and limited targeting capacity remain, though new formulations like films and hydrogels may help address these issues 257.
Antifungal Peptides and Proteins
Antifungal peptides (AFPs) and small cationic proteins from fungi are emerging as promising alternatives to traditional antifungals. These molecules have broad-spectrum activity, rapid action, and a low tendency for resistance development. Studies have shown that AFPs can reduce fungal burden and inflammation in skin infection models, suggesting potential for topical treatment of yeast infections. However, further research is needed to optimize their stability, delivery, and safety for clinical use 89.
Targeting Fungal Morphogenesis and Virulence
New therapeutic strategies are also focusing on targeting the morphogenesis and virulence factors of Candida species. By interfering with the ability of these yeasts to change form or form biofilms, these approaches may enhance susceptibility to antifungal drugs and reduce infection severity .
Conclusion
Treating yeast infections relies on a range of antifungal drugs, but increasing resistance and side effects are driving the search for new and alternative therapies. Novel antifungal agents, natural products, antifungal peptides, and strategies targeting fungal virulence are all being actively explored to improve outcomes for patients with yeast infections 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic